General M&A saw a surge in deal value this week, while PE transactions turned in some of their worst numbers so far this year.

There were 418 global announced M&A deals this week, according to preliminary data from Thomson Reuters. The 418 deals are valued at roughly $53 billion, a near 74% jump from last week.

Some big transactions helped global deal value. Nestle’s $11.9 billion buy of Pfizer Nutrition easily emerged as the largest deal of the week, while Watson Pharmaceuticals $6 billion buy of Actavis Group came in second.

Over in the PE world, things weren’t just quiet but downright dormant. The sector saw 40 announced global transactions, totaling about $3 billion. The 40 transactions are the fewest number of deals announced, during a weekly span, for all of 2012. Deal value is also rough and is the fourth lowest so far this year, according to data from Thomson Reuters. But this could change. The information is preliminary and the numbers could inch up as TR, the publisher of peHUB, gets more info (like more deals or more info on deals).

Here’s the week’s top PE-based deals.

5. Intas Pharmaceutical

The week’s fifth largest deal came from ChrysCapital, a PE firm located in Mauritius. ChrysCapital manages $2.5 billion across six funds.

ChrysCapital is investing about $57 million in Intas Pharmaceutical, an Ahmedabad-based drug maker that has reportedly chosen to defer its IPO. With the investment, ChrysCapital boosts its stake in Intas to more than 15% from 11.3%, according to The Economic Times.

Photo of Sleeping dog courtesy of Shutterstock

Related posts:

  1. 99 Cents Takes $1.6B Ares Buyout Deal
  2. Riverside Takes Pareto Private in $108M Deal
  3. Chicago Midway Airport Deal Dies
  4. Like a Stone: PE Deal-Making & Fund-Raising Volume Sink in Q3
  5. Footing The Bill: First-Half Sponsor Fees By Industry, Deal Size